Solid state, pulsed‐wave 355 nm UV laser atherectomy debulking in the treatment of infrainguinal peripheral arterial disease: The Pathfinder Registry
Catheterization and Cardiovascular Interventions · 2024
DOI: 10.1002/ccd.31023 ↗At a glance
Multizentrische Studie in Catheterization and Cardiovascular Interventions, 2024. Written by Tony S Das and 10 co-authors. Institution: The Heart Hospital Baylor Plano, Plano, Texas, USA. Major MEDLINE topics: Registries, Peripheral Arterial Disease, Atherectomy. Cited 2 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: AngioDynamics, Inc..
Abstract (original language)
Background
Atherectomy is an important option for debulking atherosclerotic plaque from diseased arteries in patients with infrainguinal arterial disease. Laser atherectomy uses a high‐powered laser to remove the plaque from the arteries to restore blood flow.
Aims
The Pathfinder multicenter registry was initiated to evaluate the safety and efficacy of the 355 nm laser atherectomy system in a real‐world setting for the treatment of de novo, re‐stenotic and in‐stent restenosis (ISR) lesions in infrainguinal arteries of patients with peripheral artery disease (PAD).
Methods
The study was a prospective, single‐arm, multicenter, open‐label registry study for patients treated with the 355 nm laser system. Clinical and lesion characteristics, procedural safety and efficacy data, and baseline, 6‐, and 12‐month outcomes data, including Ankle Brachial Index (ABI), Rutherford class, and Walking Impairment Questionnaires (WIQ), were collected. The primary efficacy endpoint was the achievement of ≤30% final residual stenosis at the index lesion postatherectomy and adjunctive therapy evaluated by an angiographic Core Lab. The primary safety endpoint was the percentage of subjects who did not experience periprocedural major adverse events (PPMAEs) before discharge.
Results
One hundred and two subjects with 121 lesions treated with the 355 nm laser device at 10 centers were included in the analysis. Mean age was 68.4 ± 10.21 years, 61.8% of subjects were male, 44.6% had critical limb ischemia (CLI), and 47.3% had tibial lesions. The mean residual stenosis at the end of the procedure was 24.4 ± 15.5 with 69 lesions (69.0%) achieving technical procedural success (
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- The Heart Hospital Baylor Plano, Plano, Texas, USA.
- Midwest Cardiovascular Research Foundation, Davenport, Iowa, USA.
- The Texas Cardiac and Vascular Institute, Corpus Christi, Texas, USA.
- Amavita Heart and Vascular Health, Miami, Florida, USA.
- Pulse Cardiovascular Institute, Scottsdale, Arizona, USA.
- Pima Heart and Vascular, Tucson, Arizona, USA.
ORCID profiles: Tony S Das, Nicolas W Shammas, Jason A Yoho, Zaheed Tai, John Rundback
Funding
- AngioDynamics, Inc.
Cite
APA
Das, T. S., Shammas, N. W., Yoho, J. A., Martinez-Clark, P., Ramaiah, V., Leon, L. R., Pacanowski, J. P., Tai, Z., Ali, V., Arslan, B., & Rundback, J. (2024). Solid state, pulsed‐wave 355 nm UV laser atherectomy debulking in the treatment of infrainguinal peripheral arterial disease: The Pathfinder Registry. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31023
Vancouver
Das TS, Shammas NW, Yoho JA, Martinez-Clark P, Ramaiah V, Leon LR, et al. Solid state, pulsed‐wave 355 nm UV laser atherectomy debulking in the treatment of infrainguinal peripheral arterial disease: The Pathfinder Registry. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31023
BibTeX
@article{Das2024,
author = {Das, Tony S and Shammas, Nicolas W and Yoho, Jason A and Martinez-Clark, Pedro and Ramaiah, Venkatesh and Leon, Luis R and Pacanowski, John P and Tai, Zaheed and Ali, Vaqar and Arslan, Bulent and Rundback, John},
title = {Solid state, pulsed‐wave 355 nm UV laser atherectomy debulking in the treatment of infrainguinal peripheral arterial disease: The Pathfinder Registry},
journal = {Catheterization and Cardiovascular Interventions},
year = {2024},
doi = {10.1002/ccd.31023}
}
EUVIMED